Charles River Laboratories International Inc
Charles River Laboratories International Inc (CRL) Covered Calls
Charles River Laboratories International Inc trades in the Diagnostics & Research industry with an IV Rank of 53.97%, average versus the past year. CRL's highest covered call setup is the $360.00 strike expiring Nov 20, 2026, sorted by theoretical annualized return. It's 8.03% out of the money with 2 days to expiration, a 8.04% return until expiration, and a 1,467.67% theoretical annualized return. Across the setups shown, annualized returns run from 180.17% to 1,467.67% at strikes between $340.00 and $540.00, with 2 to 93 days to expiration, as of Nov 18, 2026.
Read more
Running CRL covered calls helps you generate income from Charles River Laboratories International Inc shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best CRL covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.
A covered call pairs limited risk with a clear income profile. If CRL stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling CRL covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given CRL covered call is worth writing.
Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services.
| 2026-11-20 | 2 | 360.00 | 8.03 | 0.05 | 3.80 | 2680.00 | 8.04 | 1467.67 | -0.02 | +0.16 | 28 | 3.75 |
| 2026-11-20 | 2 | 350.00 | 5.03 | 0.40 | 4.20 | 1715.00 | 5.15 | 939.20 | -0.12 | +0.21 | 876 | 3.80 |
| 2026-11-20 | 2 | 340.00 | 2.03 | 2.25 | 5.50 | 900.00 | 2.70 | 492.87 | -0.68 | +0.35 | 105 | 3.25 |
| 2026-12-18 | 30 | 400.00 | 20.03 | 0.35 | 4.70 | 6710.00 | 20.14 | 244.98 | -0.11 | +0.12 | 106 | 4.35 |
| 2027-02-19 | 93 | 540.00 | 62.04 | 0.30 | 4.20 | 20705.00 | 62.13 | 243.85 | -0.09 | +0.06 | 0 | 3.90 |
| 2027-02-19 | 93 | 520.00 | 56.04 | 0.80 | 4.50 | 18755.00 | 56.28 | 220.88 | -0.24 | +0.07 | 0 | 3.70 |
| 2026-12-18 | 30 | 390.00 | 17.03 | 1.30 | 5.60 | 5805.00 | 17.42 | 211.94 | -0.39 | +0.15 | 7 | 4.30 |
| 2027-02-19 | 93 | 500.00 | 50.04 | 1.55 | 5.30 | 16830.00 | 50.50 | 198.21 | -0.47 | +0.09 | 7 | 3.75 |
| 2027-02-19 | 93 | 490.00 | 47.04 | 2.05 | 5.50 | 15880.00 | 47.65 | 187.02 | -0.62 | +0.10 | 0 | 3.45 |
| 2026-12-18 | 30 | 380.00 | 14.03 | 2.60 | 6.90 | 4935.00 | 14.81 | 180.17 | -0.78 | +0.20 | 119 | 4.30 |
As of Nov 18, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →Stock Statistics
- IndustryDiagnostics & Research
- SectorHealthcare
- IV Rank53.97% Moderate
- Market cap (M$)15,714
- 52 weeks high-13.62%
- 52 weeks low124.30%
- Analyst recommendationBuy
1.85 - Target price$368.07
12.24% above the current stock price - Dividend—
- Payout ratio—
- Earnings date2027-02-17
- P/E363.48
- Future P/E25.37
- EPS (ttm)0.90
- EPS growth next 5 years12.17%
As of Nov 19, 2026